Expression and clinical significance of WT1 in patients with different types of myeloproliferative neoplasm

ObjectiveTo explore the differential expression levels of WT1 in patients with different subtypes of myeloproliferative neoplasm (MPN), and to summarize the expression characteristics of WT1 in MPN, especially the correlation between the relative expression level of the WT1 gene and the progression of chronic myeloid leukemia (CML).

MethodsFluorescence quantitative PCR (RQ-PCR) was used to detect the gene expression types of 56 MPN patients, as well as the relative expression levels of the P210 gene and WT1 gene.The expression characteristics of WT1 in MPN of different gene types were analyzed.

ResultsThere was a statistically significant difference in the WT1 positive rate between the CML group and the non-CML group (P < 0.01), and there was also a statistically significant difference in the WT1 value between the CML group and the non-CML group (P < 0.01).The positive rate of WT1 in the P210+ group was higher than that in the non-P210+group (P < 0.01), and the WT1 value of WT1 positive cases in the P210+ group was also significantly different from that in the non-P210+ group (P < 0.01).The expression differences of WT1 and P210 genes at different stages of CML disease progression were statistically significant (P < 0.01).The value of WT1 significantly increased as CML entered the acceleration phase, while the value of WT1 significantly decreased during partial remission.

ConclusionsWT1 gene expression in MPN has some differences, moreover, the WT1 relative expression level of P210+ CML patients can be used as an index to judge the CML progress together with the relative expression level of P210 gene.